

O. Stanger
W. Herrmann
K. Pietrzik
B. Fowler
J. Geisel
J. Dierkes
M. Weger

Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases

Über den rationellen klinischen Umgang mit Homocystein, Folsäure und B-Vitaminen bei kardio-vaskulären und thrombotischen Erkrankungen

Received: 12 May 2003
Accepted: 17 December 2003

Prof. Dr. med. Olaf Stanger (✉)
Universitätsklinik für Herzchirurgie
Private Medizinische Universität (PMU)
Landeskliniken Salzburg
Müllner Hauptstraße 48
5020 Salzburg, Austria
Tel.: 00 43-6 62 / 44 82-5 75 12
Fax: 00 43-6 62 / 82 83 18
E-Mail: o.stanger@lks.at

W. Herrmann · J. Geisel
Zentrallabor, Bldg 40
Universitätsklinik des Saarlandes
Homburg, Germany

K. Pietrzik
Institut für Ernährungswissenschaften
Rheinische Friedrichs-Wilhelm-Universität
Bonn, Germany

B. Fowler
Universitäts-Kinderspital beider Basel
Basel, Switzerland

J. Dierkes
Institut für Klinische Chemie
Otto-von-Guericke-Universität Magdeburg
Magdeburg, Germany

M. Weger
Universitäts-Augenklinik
LKH Graz
Graz, Austria
on behalf of the D.A.CH.-LIGA
Homocystein e.V.
(German, Austrian, and Swiss
Homocysteine Society
www.dach.liga-homocystein.org)

■ **Zusammenfassung** Etwa die Hälfte aller Todesfälle sind auf Herz-Kreislauf-Erkrankungen bzw. deren Komplikationen zurückzuführen. Volkswirtschaft und Gesundheitswesen werden zusätzlich durch gewaltige Kosten für Arbeitsausfälle, Folgeerkrankungen und -behandlungen belastet, besonders unter dem Aspekt einer raschen Zunahme älterer Bevölkerungsschichten. Nachdem die konventionellen Risikofaktoren einen Teil der Fälle nicht erklären können, wird dem „neuen“ Risikofaktor Homocystein großes Interesse entgegen gebracht. Homocystein ist ein schwefelhaltiges Intermediärprodukt im Stoffwechsel der essentiellen Aminosäure Methionin. Defizite der Vitamine Folsäure, Vitamin B₁₂ und B₆ sowie eingeschränkte Enzymaktivitäten führen durch Abbauehemmung zur intrazellulären Konzentrationserhöhung von Homocystein. Zahlreiche retrospektive und prospektive Studien finden übereinstimmend eine unabhängige Beziehung zwischen bereits leicht erhöhtem Homocystein und kardiovaskulären Erkrankungen sowie der Gesamtmortalität. Eine Risikoerhöhung ist ab einem Homocysteinwert von etwa 9 µmol/l in einer linearen Dosis-Wirkungsbeziehung ohne Schwellenwert darstellbar. Die Hyperhomocysteinämie als

unabhängiger Risikofaktor für Herz-Kreislauf-Erkrankungen wird für etwa 10% des Gesamtrisikos verantwortlich gemacht. Erhöhte Konzentrationen (moderate Hyperhomocysteinämie, >12 µmol/l) gelten als zelltoxisch und werden bei 5–10% der Allgemeinbevölkerung und bei bis zu 40% der Patienten mit Gefäßerkrankungen gemessen. Zusätzliche Risikofaktoren (Rauchen, arterieller Hypertonus, Diabetes und Hyperlipidämie) können das Gesamtrisiko additiv oder durch Interaktion mit Homocystein synergistisch und überproportional erhöhen. Bei Hyperhomocysteinämie kommt es neben Veränderungen der Gefäßmorphologie zu einem Verlust der antithrombotischen Endothelfunktion und zur Induktion eines prokoagulatorischen Milieus. Den meisten der bekannten Schädigungen liegen Homocystein-vermittelte oxidative Stressbelastungen zugrunde. Zahlreiche Wirkstoffe, Medikamente, Erkrankungen und Lebensstilfaktoren beeinflussen den Homocystein-Stoffwechsel, zumeist als direkte oder indirekte Antagonisten von Kofaktoren und Enzymaktivitäten. Als häufigste Ursache erhöhter Homocysteinwerte gilt der Folsäuremangel. Die ausreichende Versorgung mit mindestens 400 µg Folat/Tag ist auch bei ausgewogener Ernäh-

rung schwierig und besonders für Risikogruppen häufig nicht realisierbar. Aufgrund der bereits vorliegenden Erkenntnisse wird zunehmend die Bestimmung und Behandlung erhöhter Homocysteinkonzentrationen bei Hochrisikogruppen und besonders von Patienten mit manifesten Gefäß-erkrankungen gefordert. In beiden Fällen sollte zunächst eine Homocysteinbestimmung durchgeführt werden (Ausgangswert). Außer bei Manifestationen richtet sich das weitere Vorgehen nach dem Befund (Grafik). In Übereinstimmung mit anderen Arbeits- und Konsensusgruppen ist als Therapieziel ein Homocysteinspiegel $< 10 \mu\text{mol/l}$ anzustreben. Durch Senkung erhöhter Homocysteinspiegel könnten, basierend auf verschiedenen Berechnungsgrundlagen, theoretisch bis zu 25% der kardiovaskulären Ereignisse vermieden werden. Auf Grund der billigen, potentiell effektiven und nebenwirkungsfreien Therapiemöglichkeit besteht ein außerordentlich günstiger Kosten-Nutzen-Quotient. Vor einer möglichen Empfehlung für die generelle Bestimmung und Behandlung erhöhter Homocysteinwerte bei Gesunden müssen erst die Ergebnisse derzeit laufender kontrolliert-randomisierter Interventionsstudien bekannt sein.

■ **Schlüsselwörter** Homocystein – Hyperhomocysteinämie – Vitamin B₁₂ – Folat – Therapie

■ **Summary** About half of all deaths are due to cardiovascular disease and its complications. The economic burden on society and the healthcare system from cardiovascular disability, complications, and treatments is huge and becoming larger in the rapidly aging populations of developed coun-

tries. As conventional risk factors fail to account for part of the cases, homocysteine, a “new” risk factor, is being viewed with mounting interest.

Homocysteine is a sulfur-containing intermediate product in the normal metabolism of methionine, an essential amino acid. Folic acid, vitamin B₁₂, and vitamin B₆ deficiency and reduced enzyme activities inhibit the breakdown of homocysteine, thus increasing the intracellular homocysteine concentration. Numerous retrospective and prospective studies have consistently found an independent relationship between mild hyperhomocysteinemia and cardiovascular disease or all-cause mortality. Starting at a plasma homocysteine concentration of approximately $10 \mu\text{mol/l}$, the risk increase follows a linear dose-response relationship with no specific threshold level. Hyperhomocysteinemia as an independent risk factor for cardiovascular disease is thought to be responsible for about 10 percent of total risk. Elevated plasma homocysteine levels ($> 12 \mu\text{mol/l}$; moderate hyperhomocysteinemia) are considered cytotoxic and are found in 5 to 10 percent of the general population and in up to 40 percent of patients with vascular disease. Additional risk factors (smoking, arterial hypertension, diabetes, and hyperlipidemia) may additively or, by interacting with homocysteine, synergistically (and hence overproportionally) increase overall risk. Hyperhomocysteinemia is associated with alterations in vascular morphology, loss of endothelial antithrombotic function, and induction of a pro-coagulant environment. Most known forms of damage or injury are due to homocysteine-mediated oxidative stresses. Especially when

acting as direct or indirect antagonists of cofactors and enzyme activities, numerous agents, drugs, diseases, and life style factors have an impact on homocysteine metabolism. Folic acid deficiency is considered the most common cause of hyperhomocysteinemia. An adequate intake of at least $400 \mu\text{g}$ of folate per day is difficult to maintain even with a balanced diet, and high-risk groups often find it impossible to meet these folate requirements. Based on the available evidence, there is an increasing call for the diagnosis and treatment of elevated homocysteine levels in high-risk individuals in general and patients with manifest vascular disease in particular. Subjects of both populations should first have a baseline homocysteine assay. Except where manifestations are already present, intervention, if any, should be guided by the severity of hyperhomocysteinemia. Consistent with other working parties and consensus groups, we recommend a target plasma homocysteine level of $< 10 \mu\text{mol/l}$. Based on various calculation models, reduction of elevated plasma homocysteine concentrations may theoretically prevent up to 25 percent of cardiovascular events. Supplementation is inexpensive, potentially effective, and devoid of adverse effects and, therefore, has an exceptionally favorable benefit/risk ratio. The results of ongoing randomized controlled intervention trials must be available before screening for and treatment of hyperhomocysteinemia can be recommended for the apparently healthy general population.

■ **Key words** Homocysteine – hyperhomocysteinemia – vitamin B₁₂ – folate – therapy

Introduction

Each year about 4 million Europeans die from cardiovascular disease and its complications (CAD, PAOD, myocardial infarction, stroke, venous thrombosis). In the three D.A.CH. countries (Germany, Austria, Switzerland), there were 443 498 cardiovascular deaths in 2001 (www.statistik.at, www.destatis.de, www.statistik.admin.ch), accounting for 46 percent of all deaths there [51, 85]. The economic burden on society and the healthcare system from cardiovascular disability, complications, and treatments is huge and becoming larger in the rapidly aging populations of developed countries [27, 50, 55, 85]. Atherosclerosis is today considered a chronic condition that progresses in bouts rather than as a continuous process [84]. Atherosclerosis is often detectable at a youthful age and therefore amenable to early, efficient prophylaxis [7, 8]. There is therefore an increasing call for starting risk factor identification at age 20, and absolute individual risk should be known when a person turns 40 [46, 101].

Hyperhomocysteinemia as an independent risk factor for cardiovascular disease is thought to be responsible for about 10 percent of total risk [9, 36]. Based on various calculation models, reduction of elevated plasma homocysteine concentrations may prevent up to 25 percent of cardiovascular events [65, 105, 107]. Based on the available evidence, there is an increasing call for the diagnosis and treatment of elevated homocysteine levels in high-risk populations [20, 21, 28, 36, 55, 109]. The results of ongoing randomized controlled intervention trials must be


available before screening for and treatment of hyperhomocysteinemia can be recommended for the apparently healthy general population [14]. Apart from its significance as an independent risk factor of additional prognostic value, homocysteine is a sensitive diagnostic indicator of folate, vitamin B₁₂, and vitamin B₆ deficiencies [15, 69, 103]. The determination of the plasma homocysteine concentration is also useful for documenting response to vitamin supplementation.

The purpose of this consensus paper is to provide orientation on how to handle the risk factor homocysteine in terms of its diagnostic and clinical role in atherothrombotic conditions and the need for therapeutic intervention.

Metabolism and pathobiochemistry

Homocysteine is a sulfur-containing intermediate product in the normal metabolism of methionine, an essential amino acid (Fig. 1). "Activated" S-adenosyl-methionine (SAM) is the most important methyl donor in numerous biological reactions (DNA, proteins, neurotransmitters, hormones, phospholipids) [13]. Acquiring a methyl group from 5-methyltetrahydrofolate (5-methyl-THF), homocysteine is remethylated to methionine. This reaction is catalyzed by the enzyme methionine synthase, and vitamin B₁₂ is required as a cofactor. Alternatively, homocysteine can, by condensation with serine and via cystathionine, be irreversibly broken down to cysteine and

Fig. 1 Homocysteine metabolism
 (THF tetrahydrofolate, A methyl transferases, B 5,10-methylenetetrahydrofolate reductase)



glutathione (transsulfuration). The activities of both enzymes involved in this metabolic pathway, i.e., cystathionine beta-synthase (CBS) and gamma-cystathionase, depend on the cofactor vitamin B₆.

In addition to their functions as cofactors for the enzymes involved in homocysteine metabolism, vitamins B₁₂, B₆, and folic acid have yet other important, independent properties [5, 11, 82, 106]. Folic acid and vitamin B₆ deficiencies are independent risk factors for cardiovascular disease. Apart from being involved in the development of hyperhomocysteinemia, folate deficiency is associated with hypomethylation, DNA damage (chromosome strand breaks), or impaired cell proliferation with an increased risk of malignant disease [48, 96]. As vitamin B₁₂ acts as a cofactor for methionine synthase and is involved in folate metabolism, vitamin B₁₂ deficiency may, even with adequate folate intake, lead to reduced remethylation as well as to hypomethylation [91]. This results in elevated plasma homocysteine levels and functional folate deficiency despite (seemingly) adequate plasma folic acid concentrations (because folate is "trapped" as methyltetrahydrofolate).

Folic acid, vitamin B₁₂, and vitamin B₆ deficiencies and reduced enzyme activities inhibit the breakdown of homocysteine, thus increasing the concentration of intracellular homocysteine [26, 44, 90]. Being cytotoxic, homocysteine is increasingly exported from the cell to become detectable in plasma.

Homocysteine is present in plasma (serum) in various forms in different proportions. The free, reduced form accounts for less than 2 percent, while most homocysteine in plasma is present in the oxidized form bound to albumin or as the disulfide [78]. Only minute amounts of homocysteine are found in the urine of healthy subjects. The term "homocystinuria" should therefore be reserved for inborn errors of metabolism characterized by extremely elevated plasma homocysteine levels and substantially increased excretion of homocysteine in the urine.

Homocysteine as a risk factor

Numerous retrospective and prospective studies have consistently found an independent relationship between mild hyperhomocysteinemia (fasting or after oral methionine loading) and cardiovascular disease or all-cause mortality [9, 20, 26, 68, 95, 105, 108]. Starting at a plasma homocysteine concentration of approximately 10 µmol/l, an associated risk increase follows a linear dose-response relationship with no specific threshold level [7, 9, 59, 69, 96, 109]. Practically all essential criteria for a causal association [40] between

cardiovascular events and elevated homocysteine concentrations are considered met [9, 107]. The importance of homocysteine as a risk factor is approximately equivalent to that of smoking or hyperlipidemia [9, 36]; relative risk is at least 1.3 to 1.7 for a 5 µmol/l increase in plasma homocysteine [26, 105] and is further increased in preexisting vascular disease. Meta-analyses have calculated that homocysteine is responsible for at least 10 percent of the total risk for atherothrombotic vascular disease [36, 65, 107].

Evidence from epidemiological studies suggests an increased risk for venous thrombosis with elevated homocysteine concentrations [22, 52, 107]. In meta-analyses, the odds ratio for venous thrombosis was calculated to be 1.6 (1.1–2.2) for a 5 µmol/l increase in plasma homocysteine and to be 2.5 (1.8–3.5) respectively, for fasting plasma homocysteine levels above the 95th percentile compared with the control group [22, 107]. Furthermore, hyperhomocysteinemia may increase the risk associated with some inherited disorders. In a 10-year prospective study, the risk for idiopathic thrombosis increased in carriers of factor V Leiden mutation from 4-fold to 22-fold when subjects were hyperhomocysteinemic [80]. Recent studies suggested an independent association between low folate and vitamin B₁₂ status and the risk of venous thromboembolism [72, 77].

Additional risk factors (smoking, arterial hypertension, diabetes, and hyperlipidemia) may additionally or, by interacting with homocysteine, synergistically (and hence overproportionally) increase overall risk [3, 26, 30, 36, 73]. Meta-analyses have calculated that a 3 to 5 µmol/l reduction in plasma homocysteine may reduce the incidence of venous thrombosis, stroke, and CAD mortality by up to 25 percent [105, 107].

Causes of hyperhomocysteinemia

■ Age and gender

Plasma homocysteine increases with age, and younger men normally have higher levels than women of the same age. In people around age 40, the gender difference is approximately 2 µmol/l and can be explained by the effect of estrogen in women because this difference disappears rapidly after menopause. The age-related increase in plasma homocysteine can be explained, at least in part, by the physiologic decline in renal function with age. Plasma homocysteine levels show an essentially linear increase up to age 60–65 but a much faster rise thereafter, increasing by approximately 10 percent or 1 µmol/l per decade [20, 26].

■ Genetic factors

The enzyme 5,10-methylenetetrahydrofolate reductase (MTHFR) irreversibly reduces 5,10-methylene-THF to 5-methyl-THF. About 5 to 15 percent of the general population in Germany, Austria, and Switzerland are homozygous carriers of a thermolabile variant of MTHFR that is due to a point mutation at nucleotide position 677 (MTHFR 677C → T) [32]. MTHFR activity is reduced by approximately 70 percent in affected individuals. Carriers of the mutation are therefore particularly sensitive to folate deficiency, experiencing an increase in plasma homocysteine by approximately 25 percent (or about 2.6 $\mu\text{mol/l}$) [44]. Recent meta-analyses including sufficiently large numbers of cases have found an associated 16 to 23 percent risk increase for homozygotes, explained by the plasma homocysteine increase or folate deficiency [47, 49, 63, 107]. Approximately 1 percent of the general population are heterozygotes for mutations in the CBS gene. Carriers of this mutation show elevated homocysteine concentrations after oral methionine loading and also have an increased risk for vascular disease [109]. Other mutations with a possible impact on homocysteine metabolism (methionine synthase [53], methionine synthase reductase [111], etc.) are very rare, and their clinical significance is all but unexplored.

■ Vitamin deficiency

Vitamin deficiency is by far the leading cause of hyperhomocysteinemia, and it may be due to inadequate intake, reduced absorption from the gastrointestinal tract, increased consumption, and (drug) interactions. Individuals who do not eat a balanced diet (e.g., vegetarians), elderly people, pregnant women, patients with renal disease, malabsorption (inflammatory bowel disease) or malignant disease are at risk for clinically significant vitamin deficiency. In addition, alcohol abuse and use of certain drugs (see Table 1) may lead to vitamin deficiency. Folate deficiency is the most common vitamin deficiency in Europe, partly because of a lack of fresh fruits and vegetables. Good dietary sources of folates include green vegetables, cereals, fruits, yeast, and liver (with reservations). However, up to 90 percent of folates may be lost during processing of cereals and other foods [89]. Folates are also lost because folic acid is sensitive to heat, storage, and light. A number of professional associations recommend five servings of fruits and vegetables a day (600–700 g), but most people find it all but impossible to comply with this recommendation. An average daily intake

of approximately 400 μg of dietary folate equivalents (DFE) would optimize all folate-dependent metabolic parameters (e.g., homocysteine). However, the average daily dietary folate intake in Germany, Austria, and Switzerland is currently clearly below 300 μg (197 to 235 μg for men and 168 to 214 μg for women) [19] so that a large proportion of the general population fails to attain the required natural dietary folate intake [4].

Vitamin B₁₂ intake usually exceeds requirements. High-risk populations may still experience problems. Vitamin B₁₂ deficiency in elderly people is frequently due to inadequate absorption resulting from an age-related decrease in gastric acid secretion or a slight increase in (gastric) pH, or to intrinsic factor deficiency, and may affect as many as 30 to 40 percent of the elderly population [58, 90]. As vitamin B₁₂ can only be synthesized by bacteria, animal foods (fish, meat, eggs, dairy products) are the only good sources of vitamin B₁₂ [38]. Unlike folate, cobalamin is a relatively stable vitamin and almost all of it is left intact by food processing.

Meat, dairy products, wholemeal cereals, potatoes, fruits, and vegetables are particularly rich in vitamin B₆ [37]. No representative surveys of vitamin B₆ intake in Germany, Austria, and Switzerland are available. Data from the Framingham Heart Study show a significant increase in plasma homocysteine levels for vitamin B₆ intakes of less than approximately 1.4 mg/day [34]. Vitamin B₆ shows greater stability than folic acid: Not more than 10 to 50 percent of vitamin B₆ is lost during storage and cooking [37].

■ Other causes of changes in plasma homocysteine

Numerous agents, drugs, diseases, and life style factors have an impact on homocysteine metabolism, especially when acting as direct or indirect antagonists of cofactors and enzyme activities but also as a consequence of disulfide exchange reactions, impairment of absorption, and enzyme induction [26, 70]. Most of the resultant clinically significant changes may therefore be important to interpreting the overall clinical picture. Moreover, plasma homocysteine levels are a useful indicator of the efficiency of some treatments (Table 1).

Mechanisms of homocysteine-mediated vascular damage (atherothrombosis)

Homocysteine metabolism in cardiovascular cells relies exclusively on folate and vitamin B₁₂ dependent remethylation since no transsulfuration has to date

Table 1 Causes of plasma homocysteine (Hcy) changes

Cause	Hcy	Mechanism
<i>Drugs</i>		
Theophylline	↑	Vitamin B ₆ antagonist; inhibits pyridoxal kinase
Nitrous Oxide (N ₂ O)	↑	Oxidation of cobalt, cobalamin and MS inactivation
<i>Lipid Lowering Drugs</i>		
Fibrates	↑	PPAR α activation? Renal function?
Niacin	↑	Vitamin B ₆ antagonist; inhibits pyridoxal kinase
Colestipol/cholestyramine	↑	Impairment of folic acid and cobalamin absorption
<i>Antifolates</i>		
Methotrexate	↑	Inhibits dihydrofolate reductase, folic acid antagonist
Trimethoprim	↑	Inhibits dihydrofolate reductase
<i>Hormones</i>		
Postmenopausal HRT	↓	Estrogen effect
Oral contraceptives	↑ (?)	Interference with folic acid? (relevance still unclear)
Antiepileptic drugs	↑	Folic acid antagonism, enzyme modulation
Metformin	↑	Inhibition of vitamin B ₁₂ absorption, binding of Ca ²⁺
Omeprazole	↑	Impairment of vitamin B ₁₂ absorption
Mesna	↓	Disulfide exchange
Levodopa	↑	Levodopa is a substrate for SAM-dependent methylation
D-Penicillamine	↓	Disulfide exchange
N-Acetylcysteine	↓	Disulfide exchange
<i>Antiestrogens</i>		
Tamoxifen	↓	Partial estrogen antagonist, enzyme induction?
Raloxifene	↓	Enzyme induction?
Aminoglutethimide	↑	Enzyme induction?
Cyclosporin A	↑	Renal function?
Sulfasalazine	↑	Inhibits dihydrofolate reductase and folate absorption
Isoniazid	↑	Vitamin B ₆ antagonist through complex formation
<i>(Hyper)proliferative Conditions</i>		
Psoriasis	↑	Cell proliferation
Acute lymphocytic leukemia	↑	Cell proliferation
Rheumatoid arthritis	↑	Cell proliferation
<i>Thyroid Disorders</i>		
Hypothyroidism	↑	Enzyme induction
Hyperthyroidism	↓	Enzyme induction
<i>Renal Impairment</i>	↑↑	Impaired remethylation
<i>Smoking</i>	↑	Interference with vitamin B ₆ , B ₁₂ , and folate; redox
<i>Coffee/Caffeine</i>	↑	Vitamin B ₆ antagonist (caffeine), methyl group requirements ↑
<i>Alcohol</i>	—	Interference with vitamin B ₆ , B ₁₂ , and folate; enzyme inhibition

been demonstrated in endothelial cells of human blood vessels [12]. Because of the absence of irreversible breakdown of homocysteine to cysteine, homocysteine synthesis may rapidly exceed cell export, resulting in specific cell injury to the point of cell death. Compared with other organ systems, the cardiovascular system is therefore particularly sensitive to elevated homocysteine levels [12]. Hyperhomocysteinemia may alter vascular morphology, stimulate inflammation, activate the endothelium and the blood clotting cascade, and inhibit fibrinolysis. As a result, hyperhomocysteinemia is associated with loss of endothelial antithrombotic function and induction of a procoagulant environment [26, 98]. Most known forms of damage or injury (Table 2) are due to

homocysteine-mediated oxidative stresses. Chief among these are changes in the intracellular redox potential, interference with the NO system, and activation of transcription factors with stimulation of gene expression [99]. Numerous mechanisms are supported by in vivo studies and models of diet-induced folate deficiency and physiologic homocysteine elevation.

Table 2 Atherogenic effects of homocysteine (selection)

<i>Vascular Architecture</i>		<i>Oxidative Stress</i>	↑
Endothelial damage	↑	Production of peroxynitrite, H ₂ O ₂ , etc.	↑
VSMC proliferation	↑	Antioxidative enzymes (SOD, GPx)	↑
Collagen synthesis, fibrosis of media	↑	Lipid peroxidation	↑
Constrictive remodeling	↑	<i>Chemotaxis, Leukocyte Adhesion</i>	↑
Foam cell formation	↑	Leukocyte adhesion	↑
(Proliferative) fibrous plaques	↑	sICAM-1, VCAM-1	↑
<i>Cell Structure Damage</i>	↑	Chemotaxis (IL-8, MCP-1), vWF	↑
Mitochondrial damage	↑	<i>Clotting Activation</i>	↑
ER stress	↑	Tissue factor	↑
Metalloproteinases	↑	Inactivation of protein C	↑
Elastolysis	↑	Thrombin (thrombin-antithrombin complex)	↑
HSP-70 expression	↓	D-Dimer	↑
<i>Endothelial Dysfunction</i>	↑	<i>Fibrinolysis</i>	↓
<i>NO System</i>	↑↓	Heparin sulfate	↓
NO bioavailability	↓	Annexin II	↓
ADMA	↑	Thrombomodulin	↓
<i>Transcription Factors</i>		PAI-1, t-PA antigen	↑
Activation of NF- κ B, SREBP, PKC	↑	Prothrombin fragment F1+2	↑
Gene expression	↑↓	Inactivation of Factor Va	↓
HMG-CoA reductase	↑	<i>Platelet Aggregation</i>	↑
Lipid biosynthesis	↑	Fibronectin (function)	↓
Inactivation of PPAR α and γ	↑	COX, production of TXA ₂ and TXB ₂	↑

VSMC vascular smooth muscle cell, ER endoplasmic reticulum, HSP heat shock protein, NO nitric oxide, ADMA asymmetric dimethylarginine, SREBP sterol regulatory element binding protein, PKC protein kinase C, PPAR peroxisome proliferator-activated receptor, H₂O₂ hydrogen peroxide, SOD superoxide dismutase, GPx glutathione peroxidase, sICAM soluble intercellular adhesion molecule, VCAM vascular cell adhesion molecule, IL interleukin, MCP monocyte chemo-tactic protein, vWF von Willebrand Factor, PAI-1 plasminogen activator inhibitor 1, t-PA tissue plasminogen activator, COX cyclooxygenase, TXA₂ thromboxane A₂

Methods and sample handling

Analytical methods

A variety of methods are available for the quantitative determination of homocysteine in plasma [104]. Only a minor part of total homocysteine in plasma is present as a free, reduced form. The rest (\approx 98%) forms disulfides with homocysteine, cysteine or albumin. Available methods for the determination of homocysteine measure total plasma homocysteine (tHcy), i.e., the sum of free and bound homocysteine, after a reduction step. Sulphydryl compounds such as dithiothreitol, mercaptoethanol, tri-n-butylphosphine and others are used as reducing agents [104]. Quantitative shifts between the two fractions will therefore not show up in the reported concentration.

Most common assay techniques are based on high-pressure liquid chromatography (HPLC) and immunologic methods. In addition, the stable isotope dilution assay that uses gas chromatography-mass spectrometry (GCMS) depends on the simultaneous use of a deuterated homocysteine as an internal standard [94]. After a reduction step, homocysteine is extracted on a disposable anion-exchange chromatography column. The extract is then dried, derivatized with a tert-

butyldimethylsilyl agent and finally separated and quantified by GCMS. This method, although highly precise, is expensive and relatively time consuming. HPLC can be applied using pre- or post-column derivatization with photometric, fluorometric or electrochemical detection [1, 60]. These assays have been improved to offer a shorter run time, and a higher precision. Immunoassays initially reduce homocysteine which is then converted into S-adenosylhomocysteine using S-adenosylhomocysteine hydrolase. The quantification step depends on using monoclonal antibodies against S-adenosylhomocysteine combined with different approaches for detection [67, 92]. All of these assay methods show good concordance in patient populations but may show considerable within-subject differences.

Quality control

While there is sufficient concordance in differentiating between normohomocysteinemia and hyperhomocysteinemia, among-method variations are still unsatisfactory [60]. The mean among-laboratory and among-method variations ranged from 12.5 to 18% in a recent study that compared 6 different methods in 9 laboratories [23]. International standardization (development of a plasma standard) would be

needed to improve between-laboratory comparability and to increase the quality of assay results. Participation in an interlaboratory (roundrobin) testing program for external quality assurance (e.g., in a European Research Network for evaluation and improvement of screening, diagnosis and treatment of Inherited Metabolic Disorders (ERNDIM) quality assurance scheme; www.erndimqa.nl) would therefore be desirable and useful.

■ Sample preparation

A fasting blood sample collected into an EDTA tube should be used for the measurement of plasma homocysteine. The blood sample should be centrifuged immediately after collection to separate the plasma. If immediate centrifugation is impracticable, the blood sample can be stored on ice for not more than one hour. Failure to immediately centrifuge and separate the plasma from the blood cells causes a rapid increase in plasma homocysteine (by as much as 10% per hour) as a function of temperature and time, giving false high readings [79]. After centrifugation, homocysteine is stable in plasma (for 24 hours at room temperature, for up to one week in the refrigerator (4 °C), or for several months when deep-frozen (-20 °C)).

Serum samples should not be used because serum cannot be separated by centrifugation before the blood sample has coagulated completely. Collection tubes anticoagulated with substances other than EDTA have been used on various occasions to increase the time to centrifugation. However, as the comparability of those assay results with the readings obtained with the method described here is quite limited, the practice of immediate plasma separation by centrifugation or brief storage on ice should be followed if at all possible for the sake of better comparability of results.

■ Intraindividual variability

Intraindividual variability of homocysteine is very low. Repeat measurements after 6 to 18 months in healthy volunteers show good reproducibility of baseline levels with nonsignificant intraindividual variations of as little as 0.85 to 1.2 $\mu\text{mol/l}$ [18, 33]. Despite the low variability of homocysteine assays, repeat measurements can improve the diagnostic reliability within the range where a decision to treat or not to treat is to be made. One-time measurements, on the other hand, tend to underestimate actual risk by approximately 10 to 15 percent because of the associated misestimate of the true set-point [17].

Without appropriate correction, risk is underestimated by approximately 20 percent after 2 years and approximately 50 percent after 10 years [17]. This regression dilution increases with time, and a correction formula should be used for appropriate risk estimation in prospective clinical trials [17]. This also explains why various prospective studies have tended to underestimate relative risk compared with retrospective studies [16].

■ Oral methionine loading

Plasma homocysteine levels are measured before and 4 or 6 hours after oral methionine loading (100 mg of methionine per kg of body weight). The value measured after methionine loading mainly reflects CBS activity or vitamin B₆ availability. The fasting plasma homocysteine concentration determined without methionine loading, on the other hand, is not a good indicator of vitamin B₆ deficiency [103]. Subjects with a fasting plasma homocysteine between 12 and 15 $\mu\text{mol/l}$ often have an abnormal oral methionine loading test (>38 $\mu\text{mol/l}$) [36]. Oral methionine loading can identify more subjects with hyperhomocysteinemia than determination of fasting plasma homocysteine alone [36]. However, there are currently no generally accepted criteria for interpreting methionine loading test results so that this test can as yet not be recommended for use as a routine diagnostic tool; its use should rather be reserved for (clinical) research studies.

High-risk populations and plasma homocysteine risk ranges

■ High-risk populations and profiles

Moderate hyperhomocysteinemia (plasma homocysteine concentration >12 $\mu\text{mol/l}$) is found in 5 to 10 percent of the general population and in up to 40 percent of patients with vascular disease [26, 79, 90]. Hyperhomocysteinemia is associated with an increased risk for atherothrombotic diseases. The determination of plasma homocysteine should therefore be part of the individual risk profile for patients with cardiovascular disease. Synergistic interactions of homocysteine with additional risk factors (smoking, arterial hypertension, diabetes, hyperlipidemia) produce an overproportional increase in total risk; the identification of subjects/patients at high risk of vascular disease is therefore of particular importance [21, 36, 93]. These target populations are likely to derive particular benefit from homocysteine-lower-

Table 3 Plasma homocysteine assay target populations based on risk

Manifest Vascular Disease	Populations at Risk for Cardiovascular Disease	Populations at Risk for Vitamin Deficiency
Coronary artery disease	Family history of CVD	Elderly people
Myocardial infarction	Arterial hypertension	Vegetarians
Carotid artery atherosclerosis	Smoking habit	Inflammatory gastrointestinal conditions (gastritis, malabsorption)
Peripheral arterial occlusive disease	Hyperlipidemia	Preeclampsia
Cerebral artery atherosclerosis	Renal insufficiency	Kidney disease
Stroke	Diabetes	Alcohol abuse
Venous thrombosis	Metabolic syndrome	Unbalanced diet
Pulmonary artery embolism		Drugs (see Table 1)

ing treatments. Once diagnosed, patients with diabetes mellitus or metabolic syndrome should be treated like those with vascular manifestations. Individuals with a family history of cardiovascular disease/events are very likely to suffer manifestations of vascular disease at some point in their lives. Early screening for hyperhomocysteinemia is recommended for close relatives of patients in such high-risk populations. About 50 percent of men over age 40 and about 33 percent of women over age 40 will develop CAD [56]. This is why the plasma homocysteine concentration should be known also in apparently healthy individuals at age 50 at the latest. Other target populations for plasma homocysteine screening include people at (increased) risk for developing (atherothrombotic) vascular complications and vitamin deficiencies (Table 3).

■ Plasma homocysteine risk ranges

It is not helpful to specify reference ranges in the usual sense because plasma homocysteine levels below 10 $\mu\text{mol/l}$ are already associated with a graded increase in risk or manifestations of cardiovascular disease (dose-response relationship) [9, 25, 69]: Each 1 $\mu\text{mol/l}$ increment in plasma homocysteine concentration is associated with a 6 to 7 percent risk increase [8].

However, differentiated prophylactic and therapeutic risk ranges for cardiovascular disease can be defined for clinical practice. For the sake of simplification, plasma homocysteine levels $>12 \mu\text{mol/l}$ and $<30 \mu\text{mol/l}$ are traditionally referred to as “moderate hyperhomocysteinemia” (commonly found in people

Table 4 Classification of plasma homocysteine levels by need to treat

> 12 to $30 \mu\text{mol/l}$	Moderate hyperhomocysteinemia	Intervention required for all (apparently healthy individuals and patients)
10 to $12 \mu\text{mol/l}$	Tolerable (in healthy subjects)	Need to treat patients at increased risk
$< 10 \mu\text{mol/l}$	Safe	No need to treat (target level of intervention)

with vitamin deficiency); the range from 30 to 100 $\mu\text{mol/l}$ has been termed “intermediate hyperhomocysteinemia” (often found in individuals with homozygous enzyme defects as well as in patients with chronic kidney disease); and plasma homocysteine concentrations $>100 \mu\text{mol/l}$ are traditionally defined as “severe hyperhomocysteinemia” (typically found in individuals with severe congenital disorders or homocystinuria) [43, 45] (Table 4).

Goals of intervention

■ prophylaxis


While there is clearly an overall need to improve folic acid intake by the general population, there is currently no cogent evidence from cardiovascular outcome studies that would justify the definition of general guidelines for vitamin supplementation in apparently healthy subjects and low-risk individuals. Vitamin supplementation continues to be a recommendable option for prophylaxis. Dosages for prophylaxis are given in Fig. 2 (low-dose supplementation: folic acid, 0.2 to 0.8 mg/day; vitamin B₁₂, 3 to 100 $\mu\text{g/day}$; vitamin B₆, 2 to 25 mg/day). Also, everybody is recommended to eat a diet rich in vitamins.

Although the results of ongoing intervention studies of the impact of B vitamin supplementation on mortality reduction are not yet available, plasma homocysteine reduction (through dietary supplementation) should also be considered in apparently healthy individuals at increased risk and especially in patients with vascular disease because secondary endpoint evidence from previous intervention studies suggests potential benefit.

■ Treatment

Consistent with other working parties and consensus groups, we recommend a target plasma homocysteine level of $<10 \mu\text{mol/l}$ for patients with manifest vascular disease and high-risk individuals [4, 20, 34,

Fig. 2 Decision tree for the diagnosis and prophylaxis/treatment of hyperhomocysteinemia (does not apply to patients with renal impairment)



35, 64, 71, 75] (Fig. 2). Renal impairment and thyroid dysfunction as well as vitamin deficiency should be ruled out as the cause of hyperhomocysteinemia in individuals with plasma homocysteine levels $>12 \mu\text{mol/L}$. The factors listed in Table 1 should always be considered when interpreting findings. Thus, a significant reduction in plasma homocysteine can often be achieved by merely switching medications, making a dosage adjustment, or starting treatment for hypothyroidism.

■ Folate requirements and therapeutic options

An adequate intake of at least $400 \mu\text{g}$ of folate per day is difficult to maintain even with a balanced diet, and high-risk groups often find it impossible to meet these folate requirements [4, 19]. As the recommendation to eat a healthy diet has little or limited impact on elevated homocysteine levels, (folate)-fortified foods and/or vitamin supplements are rational and therefore recommended [4, 58]. Maintaining a total folate intake of 600 to $650 \mu\text{g/day}$, say, by supplementing $400 \mu\text{g/day}$, may help lower elevated homocysteine levels; this is usually easy to achieve with fortified foods and/or vitamin supplements [19].

The bioavailability of dietary folates is 55 percent. The RDAs recommended by German, Austrian, and Swiss nutrition societies are based on a polyglutamate to monoglutamate ratio of 60:40 and a bioavailability of 20 percent for polyglutamates and

100 percent for monoglutamates. The extent of absorption of synthetic folic acid added to foods is 90 to 95 percent and that of folic acid in supplement tablets is almost 100 percent. As the bioavailability of synthetic folic acid is about twice that of naturally occurring folates, RDAs are given in terms of dietary folate equivalents (DFE): $1 \mu\text{g}$ of DFE is equivalent to $1 \mu\text{g}$ of dietary folate or $0.5 \mu\text{g}$ of synthetic folic acid [2, 54, 58].

■ Recommendations for vitamin supplementation

The absolute and relative reductions in plasma homocysteine that can be achieved with vitamin supplementation depend on the baseline homocysteine concentration and are greater for higher baseline levels. Supplementation with 0.2 to 5 mg of folic acid per day is expected to lower plasma homocysteine by 16 to 39 percent (the average reduction for a standardized baseline concentration of $12 \mu\text{mol/L}$ is approximately 25%) [42]. Additional supplementation with vitamin B_{12} is recommended to avoid relative folate deficiency, i.e., to support folate utilization (because folate is "trapped" as methyltetrahydrofolate in relative vitamin B_{12} deficiency) [91]. Vitamin B_{12} supplementation is also recommended for prevention of neurodegenerative damage, a particular problem especially among elderly people. Based on these considerations, (long-term) supplementation of folic acid alone is discouraged. Instead, folate supplementation should always be combined with vi-

tamin B₁₂ supplementation. Vitamin B₆ has little impact on fasting plasma homocysteine levels, but it is an important cofactor in catabolic transsulfuration and, therefore, should be supplemented as well. Body (folate) stores are quite limited. Vitamin supplementation therefore needs to be administered chronically. Once folate (+ vitamin B₁₂ + vitamin B₆) supplementation is stopped, plasma homocysteine is bound to rise again.

■ **Supplementation in moderate hyperhomocysteinemia**

If plasma homocysteine determination suggests moderate hyperhomocysteinemia, a repeat measurement after 4 to 6 weeks may be useful to confirm the diagnosis. Once (moderate) hyperhomocysteinemia is established, vitamin supplementation should be started, supplementing 0.2 to 0.8 mg of folic acid, 3 to 100 µg of vitamin B₁₂ (elderly people should receive at least 100 µg because of malabsorption), and ideally also 2 to 25 mg of vitamin B₆. If this supplementation regimen lowers plasma homocysteine to <10 µmol/l within 4 weeks, repeat measurements of plasma homocysteine should be obtained first every 6 months and later on once a year. If response (i.e., plasma homocysteine reduction) is still inadequate, the dosage of folic acid should be increased to, say, 1 to 5 mg of folic acid per day (while supplementation with vitamin B₁₂ and vitamin B₆ can be continued unchanged for some time). Repeat determinations of plasma homocysteine should be performed at 4-week intervals.

■ **Possible other causes of increased vitamin requirements**

If plasma homocysteine fails to be adequately lowered despite adequate vitamin supplementation, the patient should be evaluated for vitamin deficiency, renal impairment, and thyroid dysfunction. It should be borne in mind that a (low) “normal” vitamin B₁₂ level does not rule out intracellular vitamin B₁₂ deficiency. Serum methylmalonic acid and holotranscobalamin II levels are more reliable markers of vitamin B₁₂ deficiency than is the serum vitamin B₁₂ concentration [39, 86]. Mutations of the genes encoding the enzymes involved in homocysteine metabolism may also result in increased vitamin requirements. The best known example is MTHFR 677C → T polymorphism. Other possible causes of hyperhomocysteinemia are listed in Table 1. The determination of specific metabolites, including methylmalonic acid, 2-methylcitric acid, cystathio-

nine, cysteine, and glutathione, may provide additional information about the type of disorder present in a particular patient.

■ **Supplementation in patients with renal dysfunction and enzyme deficiency**

Patients with overt renal failure (insufficiency, dialysis) may require very large vitamin doses (including 3 g of betaine/day) and still fail to achieve normal plasma homocysteine levels. Patients with no renal impairment whose plasma homocysteine is >30 µmol/l may have some form of congenital enzyme deficiency whose prevalence has been underestimated in the past. If pharmacologic doses of, say, 1 to 5 mg of folic acid, 1 mg of vitamin B₁₂, and >20 mg of vitamin B₆ fail to achieve normalization of plasma homocysteine, the patient should be referred to a specialist for further evaluation.

■ **Safety**

The toxicity of folic acid is extremely low even after prolonged use of high doses. Thus, 10 mg/day administered for 5 years has been tolerated without adverse reactions [10]. Higher doses have, in isolated instances, been associated with gastrointestinal symptoms, insomnia, irritability, excitation, and depression. Because of the theoretical risk of masking megaloblastic anemia and causing irreversible neurologic disorders, high doses of folic acid should not be administered alone without ruling out underlying vitamin B₁₂ deficiency beforehand, especially in elderly people [10]. This is why the United States Food and Nutrition Board (FNB) has defined a tolerable upper intake level (UL) of 1 mg/day of folic acid, which is considered safe even with life-long supplementation. Vitamin B₁₂ has for decades been used for the treatment of pernicious anemia, mainly by the parenteral (intravenous or intramuscular) route. In this indication, patients receive standard single doses of several hundred micrograms, often for the rest of their lives. Based on this extensive therapeutic experience, vitamin B₁₂ (cyanocobalamin and hydroxocobalamin) can be considered nontoxic. The FNB, therefore, has not specified a UL for vitamin B₁₂. Vitamin B₆ has for many years been used in the treatment of a number of conditions, and even very high doses are usually well tolerated. A UL of 100 mg/day would not be expected to be associated with side effects even with life-long use [6]. Vitamin B₆ supplementation in mild hyperhomocysteinemia typically only involves supplementation with 2

to 20 mg, and there is rarely a need to use doses of 100 mg and above.

Cost/benefit assessment

The accepted response-to-injury model of the development of atherosclerosis inherently includes the concept of reversibility through control of the agent(s) that cause(s) the injury [41, 50, 84]. There is clearly much greater prevention potential although the prevalence of cardiovascular disease is bound to increase dramatically as a consequence of the steadily increasing life expectancy [28, 29, 41, 51, 85]. Effective reduction of elevated plasma homocysteine levels by 3 to 5 $\mu\text{mol/l}$ through vitamin supplementation might reduce the relative risk for cardiovascular disease by approximately 10 percent in the general population and by as much as 25 percent in high-risk groups [58, 105]. This prevention potential is clearly supported by epidemiological data [31, 57, 81, 113] and numerous favorable study results already available for secondary endpoints, including improvement in endothelial function in healthy individuals [112] and patients [24, 97, 99, 110], slowing of progression of (carotid artery) atherosclerosis [75], and substantial reduction of the rate of coronary restenosis following percutaneous transluminal coronary angioplasty (PTCA) [87, 88]. More indirect evidence of the efficacy of plasma homocysteine reduction is provided by the observation that, in the first year after the introduction of food fortification with folic acid (140 $\mu\text{g}/100\text{ g}$) in the United States, there were 26 696 fewer deaths from myocardial in-

farction and stroke (compared with 1997) [61]. A most recent report [H. Lange, personal communication, ACC Chicago, 2003] discourages vitamin supplementation following coronary stent implantation for the time being.

Such an inexpensive and potentially effective intervention is rarely available for reducing morbidity, mortality, and associated costs [65, 100]. For all approaches to improving vitamin intake, variable yet invariably conservative calculation models have demonstrated a very favorable cost/benefit ratio [65, 66, 83, 100, 102]. Cost-effectiveness analyses are greatly dependent upon the defined baseline risk. The currently most efficient approach is therefore to screen and treat high-risk groups [66, 100]. Maximum cost-effectiveness has also been calculated for screening all men over age 45 (and women over age 55) with no known vascular disease and treatment of individuals with plasma homocysteine levels $>10\ \mu\text{mol/l}$ [65, 100]. Most models do not take account of synergistic savings although diseases and their treatment/prevention should, in fact, not be treated as isolated entities [50, 65, 100]. Thus, the reduction of CAD incidence would also include a reduced risk of cost-intensive conditions of old age, such as senile dementia and stroke, which account for about 30 percent of healthcare costs in over 85-year-olds. In addition to the cited cardiovascular disease prevention potential, improved folate and vitamin B₁₂ intake/supplementation is likely to have preventive effects on congenital malformations/birth defects, malignant disease, pernicious anemia, depression, and Alzheimer's disease. Further position papers are planned to address these issues.

References

- Andersson A, Isaksson A, Brattstrom L, Hultberg B (1993) Homocysteine and other thiols determined in plasma by HPLC and thiol-specific post-column derivatization. *Clin Chem* 39:1590-1597
- Bailey LB (1998) Dietary reference intakes for folate: the debut of dietary folate equivalents. *Nutr Rev* 56:294-299
- Becker A, Kostense PJ, Bos G, Heine RJ, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD (2003) Hyperhomocysteinaemia is associated with coronary events in type 2 diabetes. *J Intern Med* 253:293-300
- Beitz R, Mensink GB, Fischer B, Thamm M (2002) Vitamins-dietary intake and intake from dietary supplements in Germany. *Eur J Clin Nutr* 56:539-545
- Bender DA (1994) Novel functions of vitamin B₆. *Proc Nutr Soc* 53:625-630
- Bendich A, Cohen M (1990) Vitamin B₆ safety issues. *Ann N Y Acad Sci* 585:321-330
- Bostom AG, Rosenberg IH, Silbershatz H, Jacques PF, Selhub J, D'Agostino RB, Wilson PW, Wolf PA (1999) Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. *Ann Intern Med* 131:352-355
- Bots ML, Launer LJ, Lindemans J, Hoes AW, Hofman A, Witteman JC, Koudstaal PJ, Grobbee DE (1999) Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. *Arch Intern Med* 159:38-44
- Boushey CJ, Beresford SA, Omenn GS, Motulsky AG (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. *J Am Med Assoc* 274:1049-1057
- Butterworth CE, Tamura T (1989) Folic acid safety and toxicity: a brief review. *Am J Clin Nutr* 50:353-358

11. Chasan-Taber L, Selhub J, Rosenberg IH, Malinow MR, Terry P, Tishler PV, Willett W, Hennekens CH, Stampfer MJ (1996) A prospective study of folic acid and vitamin B₆ and risk of myocardial infarction in US physicians. *J Am Coll Nutr* 15:136-143
12. Chen P, Poddar R, Tipa EV, Dibello PM, Moravec CD, Robinson K, Green R, Kruger WD, Garrow TA, Jacobsen DW (1999) Homocysteine metabolism in cardiovascular cells and tissues: implications for hyperhomocysteinemia and cardiovascular disease. *Adv Enzyme Regul* 39:93-109
13. Chiang PK, Gordon RK, Tal J, Zeng GC, Doctor BP, Pardhasaradhi K, McCann PP (1996) S-Adenosylmethionine and methylation. *FASEB J* 10:471-480
14. Clarke R, Collins R (1998) Can dietary supplements with folic acid or vitamin B₆ reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. *J Cardiovasc Risk* 5:249-255
15. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I (1991) Hyperhomocysteinemia: an independent risk factor for vascular disease. *N Engl J Med* 324:1149-1155
16. Clarke R, Lewington S, Donald A, Johnston C, Refsum H, Stratton I, Jacques P, Breteler MM, Holman R (2001) Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiological studies. *J Cardiovasc Risk* 8:363-369
17. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, Peto R (1999) Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. *Am J Epidemiol* 150:341-353
18. Clarke R, Woodhouse P, Ulvik A, Frost C, Sherliker P, Refsum H, Ueland PM, Khaw KT (1998) Variability and determinants of total homocysteine concentrations in plasma in an elderly population. *Clin Chem* 44:102-107
19. De Bree A, van Dusseldorp M, Brouwer IA, van het Hof KH, Steegers-Theunissen RP (1997) Folate intake in Europe: recommended, actual and desired intake. *Eur J Clin Nutr* 51:643-660
20. De Bree A, Verschuren WM, Kromhout D, Kluijtmans LA, Blom HJ (2002) Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. *Pharmacol Rev* 54:599-618
21. De Bree A, Verschuren WM, Kromhout D, Mennen LI, Blom HJ (2002) Homocysteine and coronary heart disease: the importance of a distinction between low and high risk subjects. *Int J Epidemiol* 31:1268-1272
22. Den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM (1998) Hyperhomocysteinemia and venous thrombosis: a meta-analysis. *Thromb Haemost* 80:874-877
23. Ducros V, Candito M, Causse E, Couderc R, Demuth K, Diop ME (2002) Comparison of plasma total homocysteine determinations in 9 french hospital laboratories by using 6 different methods. *Ann Biol Clin* 60:421-428
24. Doshi SN, McDowell IF, Moat SJ, Lang D, Newcombe RG, Kredan MB, Lewis MJ, Goodfellow J (2001) Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide? *Arterioscler Thromb Vasc Biol* 21:1196-1202
25. Doshi SN, Moat SJ, McDowell IF, Lewis MJ, Goodfellow J (2002) Lowering plasma homocysteine with folic acid in cardiovascular disease: what will the trials tell us? *Atherosclerosis* 165:1-3
26. Durand P, Prost M, Loreau N, Lussier-Cacan S, Blache D (2001) Impaired homocysteine metabolism and atherothrombotic disease. *Lab Invest* 81:645-672
27. Eisenstein EL, Shaw LK, Anstrom KJ, Nelson CL, Hakim Z, Hasselblad V, Mark DB (2001) Assessing the clinical and economic burden of coronary artery disease: 1986-1998. *Med Care* 39:824-835
28. Erbel R, Siffert W, Mohlenkamp S, Schmermund A (2003) Prävention der KHK durch Risikostratifizierung. *Dtsch Med Wochenschr* 128:330-336
29. EUROASPIRE II Study Group (2001) Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II. *Eur Heart J* 22:554-572
30. Foody JM, Milberg JA, Robinson K, Pearce GL, Jacobsen DW, Sprecher DL (2000) Homocysteine and lipoprotein(a) interact to increase CAD risk in young men and women. *Arterioscler Thromb Vasc Biol* 20:493-499
31. Ford ES, Byers TE, Giles WH (1998) Serum folate and chronic disease risk: findings from a cohort of United States adults. *Int J Epidemiol* 27:592-598
32. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M et al (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. *Nat Genet* 10:111-113
33. Garg UC, Zheng ZJ, Folsom AR, Moyer YS, Tsai MY, McGovern P, Eckfeldt JH (1997) Short-term and long-term variability of plasma homocysteine measurement. *Clin Chem* 43:141-145
34. Genest J Jr (1999) Hyperhomocyst(e)inemia-determining factors and treatment. *Can J Cardiol* 15:35B-38B
35. Graham I (1999) Homocysteine in health and disease. *Ann Intern Med* 131:387-388
36. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GH (1997) Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. *J Am Med Assoc* 277:1775-1781
37. Gregory JF 3rd, Kirk JR (1981) The bioavailability of vitamin B₆ in foods. *Nutr Rev* 39:1-8
38. Herbert V (1988) Vitamin B₁₂: plant sources, requirements, and assay. *Am J Clin Nutr* 48(Suppl 3):852-858
39. Herrmann W, Schorr H, Bodis M, Knapp JB, Muller A, Stein G, Geisel J (2000) Role of homocysteine, cystathionine and methylmalonic acid measurement for diagnosis of vitamin deficiency in high-aged subjects. *Eur J Clin Invest* 30:1083-1089
40. Hill AB (1965) The environment and disease: association or causation? *Proc R Soc Med* 58:295-300
41. Höher M, Hombach V (1998) Klinische und ökonomische Kosten-Nutzen-Relation bei der Behandlung von Patienten mit koronarer Herzkrankung. *Z Kardiol* 87(Suppl 2):8-19
42. Homocysteine Lowering Trialists' Collaboration (1998) Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. *BMJ* 316:894-898
43. Jacobsen DW (1998) Homocysteine and vitamins in cardiovascular disease. *Clin Chem* 44:1833-1843
44. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R (1996) Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. *Circulation* 93:7-9
45. Kang SS, Wong PW, Malinow MR (1992) Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. *Annu Rev Nutr* 12:279-298

46. Kavey RE, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K (2003) American heart association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. *Circulation* 107:1562–1566
47. Kelly PJ, Rosand J, Kistler JP, Shih VE, Silveira S, Plomaritoglou A, Furie KL (2002) Homocysteine, MTHFR 677C → T polymorphism, and risk of ischemic stroke: results of a meta-analysis. *Neurology* 59:529–536
48. Kim Yi (1999) Folate and carcinogenesis: evidence, mechanisms, and implications. *J Nutr Biochem* 10:66–88
49. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG; MTHFR Studies Collaboration Group (2002) MTHFR 677C → T polymorphism and risk of coronary heart disease: a meta-analysis. *J Am Med Assoc* 288: 2023–2031
50. Klever-Deichert G, Hinzpeter B, Wendland G, Lauterbach K (2000) Kosten-Nutzen-Analyse einer evidenzbasierten Sekundärprävention koronarer Herzkrankheiten durch Statine. *Med Klin* 95:305–313
51. Koenig W (1998) Epidemiologie der koronaren Herzkrankheit. *Z Kardiol* 87(Suppl 2):3–7
52. Langman LJ, Ray JG, Evrosvki J, Yeo E, Cole DE (2000) Hyperhomocyst(e)inemia and the increased risk of venous thromboembolism: more evidence from a case-control study. *Arch Intern Med* 160:961–964
53. Leclerc D, Campeau E, Goyette P, Adjalla CE, Christensen B, Ross M, Eydoux P, Rosenblatt DS, Rozen R, Gravel RA (1996) Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. *Hum Mol Genet* 5:1867–1874
54. Lewis CJ, Crane NT, Wilson DB, Yetley EA (1999) Estimated folate intakes: data updated to reflect food fortification, increased bioavailability, and dietary supplement use. *Am J Clin Nutr* 70:198–207
55. Liu JL, Maniadakis N, Gray A, Rayner M (2002) The economic burden of coronary heart disease in the UK. *Heart* 88:597–603
56. Lloyd-Jones DM, Larson MG, Beiser A, Levy D (1999) Lifetime risk of developing coronary heart disease. *Lancet* 353:89–92
57. Loria CM, Ingram DD, Feldman JJ, Wright JD, Madans JH (2000) Serum folate and cardiovascular disease mortality among US men and women. *Arch Intern Med* 160:3258–3262
58. Malinow MR, Bostom AG, Krauss RM (1999) Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. *Circulation* 99:178–182
59. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G (1993) Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. *Circulation* 87:1107–1113
60. Martin SC, Tsakas-Ampatzis I, Bartlett WA, Jones AF (1999) Measurement of plasma total homocysteine by HPLC with coulometric detection. *Clin Chem* 45:150–152
61. Martin JA, Smith BL, Mathews TJ, Ventura SJ (1999) Births and deaths: preliminary data for 1998. *National Vital Statistics Reports* 47:1–48
62. McGill HC Jr, McMahan CA, Herderick EE, Malcom GT, Tracy RE, Strong JP (2000) Origin of atherosclerosis in childhood and adolescence. *Am J Clin Nutr* 72(Suppl 5):1307S–1315S
63. Meleady R, Ueland PM, Blom H, Whitehead AS, Refsum H, Daly LE, Vollset SE, Donohue C, Giesendorf B, Graham IM, Ulvik A, Zhang Y, Bjorke Monsen AL (2003) Thermolabile methylenetetrahydrofolate reductase, homocysteine, and cardiovascular disease risk: the European Concerted Action Project. *Am J Clin Nutr* 77: 63–70
64. Moghadasian MH, McManus BM, Frohlich JJ (1997) Homocyst(e)ine and coronary artery disease. Clinical evidence and genetic and metabolic background. *Arch Intern Med* 57: 2299–2308
65. Nallamothu BK, Fendrick AM, Omenn GS (2002) Homocyst(e)ine and coronary heart disease: pharmacoeconomic support for interventions to lower hyperhomocyst(e)inaemia. *Pharmacoeconomics* 20:429–442
66. Nallamothu BK, Fendrick AM, Rubenfire M, Saint S, Bandekar RR, Omenn GS (2000) Potential clinical and economic effects of homocyst(e)ine lowering. *Arch Intern Med* 160:3406–3412
67. Nexø E, Engbaek F, Ueland PM, Westby C, O’Gorman P, Johnston C, Kase BF, Guttormsen AB, Alfheim I (2000) Evaluation of novel assays in clinical chemistry: quantification of plasma total homocysteine. *Clin Chem* 46:1150–1156
68. Nurk E, Tell GS, Vollset SE, Nygard O, Refsum H, Ueland PM (2002) Plasma total homocysteine and hospitalizations for cardiovascular disease: the Hordaland Homocysteine Study. *Arch Intern Med* 162:1374–1381
69. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE (1997) Plasma homocysteine levels and mortality in patients with coronary artery disease. *N Engl J Med* 337:230–236
70. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland M, Kvale G (1995) Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. *J Am Med Assoc* 274:1526–1533
71. Oakley GP (1998) Eat right and take a multivitamin. *N Engl J Med* 338: 1060–1061
72. Obeid R, Hakki T, Jouma M, Herrmann W (2003) The risk of venous thromboembolism associated with the factor V Leiden mutation and low B-vitamin status. *Clin Chem Lab Med* 41:1357–1362
73. O’Callaghan P, Meleady R, Fitzgerald T, Graham I; European COMAC group (2002) Smoking and plasma homocysteine. *Eur Heart J* 23:1580–1586
74. Omenn GS, Beresford SA, Motulsky AG (1998) Preventing coronary heart disease: B vitamins and homocysteine. *Circulation* 97:421–424
75. Peterson JC, Spence JD (1998) Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia. *Lancet* 351:263
76. Pfeiffer CM, Huff DL, Smith SJ, Miller DT, Gunter EW (1999) Comparison of plasma total homocysteine measurements in 14 laboratories: an international study. *Clin Chem* 45: 1261–1268
77. Quere I, Perneger TV, Zittoun J, Bellet H, Gris JC, Daures JP (2000) Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case-control study. *Lancet* 359:747–752
78. Refsum H, Helland S, Ueland PM (1985) Radioenzymic determination of homocysteine in plasma and urine. *Clin Chem* 31:624–628
79. Refsum H, Ueland PM, Nygard O, Vollset SE (1998) Homocysteine and cardiovascular disease. *Annu Rev Med* 49:31–62
80. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ (1997) Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. *Circulation* 95:1777–1782

81. Rimm EB, Willett WC, Hu FB, Sampson L, Colditz GA, Manson JE, Hennekens C, Stampfer MJ (1998) Folate and vitamin B₆ from diet and supplements in relation to risk of coronary heart disease among women. *J Am Med Assoc* 279:359–364
82. Robinson K, Arheart K, Refsum H, Brattstrom L, Boers G, Ueland P, Rubba P, Palma-Reis R, Meleady R, Daly L, Witteman J, Graham I (1998) Low circulating folate and vitamin B₆ concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. *Circulation* 97: 437–443
83. Romano PS, Waitzman NJ, Scheffler RM, Pi RD (1995) Folic acid fortification of grain: an economic analysis. *Am J Public Health* 85:667–676
84. Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. *Nature* 362:801–809
85. Sans S, Kesteloot H, Kromhout D (1997) The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. *Eur Heart J* 18:1231–1248
86. Savage DG, Lindenbaum J, Stabler SP, Allen RH (1994) Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. *Am J Med* 96:239–246
87. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM (2002) Effect of homocysteine-lowering therapy with folic acid, vitamin B₁₂, and vitamin B₆ on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. *J Am Med Assoc* 288:973–979
88. Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR, Meier B, Turi ZG, Hess OM (2001) Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. *N Engl J Med* 345:1593–1600
89. Schroeder HA (1971) Losses of vitamins and trace minerals resulting from processing and preservation of foods. *Am J Clin Nutr* 24:562–573
90. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH (1993) Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. *J Am Med Assoc* 270:2693–2698
91. Shane B, Stokstad EL (1985) Vitamin B₁₂-folate interrelationships. *Annu Rev Nutr* 5:115–141
92. Shipchandler MT, Moore EG (1995) Rapid, fully automated measurement of plasma homocyst(e)ine with the Abbott IMx analyzer. *Clin Chem* 41:991–994
93. Smith SC Jr, Greenland P, Grundy SM (2000) AHA Conference Proceedings. Prevention conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: executive summary. *Circulation* 101:111–116
94. Stabler SP, Lindenbaum J, Savage DG, Allen RH (1993) Elevation of serum cystathionine levels in patients with cobalamin and folate deficiency. *Blood* 81:3404–3413
95. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH (1992) A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. *J Am Med Assoc* 268:877–881
96. Stanger O (2002) Physiology of folic acid in health and disease. *Curr Drug Metab* 3:211–223
97. Stanger O, Semmelrock HJ, Wonisch W, Bos U, Pabst E, Wascher TC (2002) Effects of folate treatment and homocysteine lowering on resistance vessel reactivity in atherosclerotic subjects. *J Pharmacol Exp Ther* 303: 158–162
98. Stanger O, Weger M, Renner W, Konetschny R (2001) Vascular dysfunction in hyperhomocyst(e)inemia. Implications for atherothrombotic disease. *Clin Chem Lab Med* 39:725–733
99. Stanger O, Weger M (2003) Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged endothelium. *Clin Chem Lab Med* 41:1444–1454
100. Tice JA, Ross E, Coxson PG, Rosenberg I, Weinstein MC, Hunink MG, Goldman PA, Williams L, Goldman L (2001) Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond. *J Am Med Assoc* 286:936–943
101. Tsimikas S, Witztum JL (2002) Shifting the diagnosis and treatment of atherosclerosis to children and young adults: a new paradigm for the 21st century. *J Am Coll Cardiol* 40:2122–2124
102. Tucker KL, Mahnken B, Wilson PW, Jacques P, Selhub J (1996) Folic acid fortification of the food supply. Potential benefits and risks for the elderly population. *J Am Med Assoc* 276:1879–1885
103. Ubbink JB, van der Merwe A, Delport R, Allen RH, Stabler SP, Riezler R, Vermaak WJ (1996) The effect of a subnormal vitamin B₆ status on homocysteine metabolism. *J Clin Invest* 98:177–184
104. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH (1993) Total homocysteine in plasma or serum: methods and clinical applications. *Clin Chem* 39:1764–1779
105. Ueland PM, Refsum H, Beresford SA, Vollset SE (2000) The controversy over homocysteine and cardiovascular risk. *Am J Clin Nutr* 72:324–332
106. Voutilainen S, Rissanen TH, Virtanen J, Lakka TA, Salonen JT (2001) Low dietary folate intake is associated with an excess incidence of acute coronary events: the kuopio ischemic heart disease risk factor study. *Circulation* 103:2674–2680
107. Wald DS, Law M, Morris JK (2002) Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. *BMJ* 325:1202–1208
108. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM (1998) Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. *Arch Intern Med* 158:862–867
109. Wilcken DE, Wilcken B (1997) The natural history of vascular disease in homocystinuria and the effects of treatment. *J Inher Metab Dis* 20: 295–300
110. Willems FF, Aengevaeren WR, Boers GH, Blom HJ, Verheugt FW (2002) Coronary endothelial function in hyperhomocysteinemia: improvement after treatment with folic acid and cobalamin in patients with coronary artery disease. *J Am Coll Cardiol* 40: 766–772
111. Wilson A, Platt R, Wu Q, Leclerc D, Christensen B, Yang H, Gravel RA, Rozen R (1999) A common variant in methionine synthase reductase combined with low cobalamin (vitamin B₁₂) increases risk for spina bifida. *Mol Genet Metab* 67:317–323
112. Woo KS, Chook P, Lolin YI, Sanderson JE, Metreweli C, Celermajer DS (1999) Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. *J Am Coll Cardiol* 34:2002–2006
113. Zeitlin A, Frishman WH, Chang CJ (1997) The association of vitamin B₁₂ and folate blood levels with mortality and cardiovascular morbidity incidence in the old old: the Bronx aging study. *Am J Ther* 4:275–281